NEUCA S.A. AI Stock Analysis
Want to see PL:NEU full AI Analyst Report?
NEUCA S.A. (NEU) AI Stock Analysis
NEUCA S.A.
(Warsaw:NEU)
The overall stock score reflects NEUCA S.A.’s steady growth and prudent capital structure, balanced against weak net profitability and recent negative trends in cash flow. Valuation and technical analysis signals are neutral to slightly cautious, reinforcing a moderate risk-reward outlook. There are no new insights from earnings calls or corporate events that would meaningfully alter the risk profile.
NEUCA S.A. (NEU) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- PLN 3.24B
- Dividend Yield
- 2.53%
- Average Volume (3M)
- 4,738
- Price to Earnings (P/E)
- 16.3
- Beta (1Y)
- 0.44
- Revenue Growth
- 8.42%
- EPS Growth
- 43.47%
- Country
- PL
- Employees
- 5,004
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
NEUCA S.A. Business Overview & Revenue Model
Company Description
NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribut...
How the Company Makes Money
NEUCA generates revenue through several key streams. The primary source of income comes from the wholesale distribution of pharmaceuticals, which involves purchasing drugs from manufacturers and selling them to pharmacies and healthcare facilities. T...
NEUCA S.A. Financial Statement Overview
Summary
NEUCA S.A. shows stable revenue growth (TTM growth 1.8%) and a conservative balance sheet with a healthy equity ratio and improving leverage. However, persistent low net profit margins (~1%), a decline in ROE, and significant volatility culminating in negative free cash flow in the most recent period raise notable concerns about sustainable profitability and operational cash efficiency.
Income Statement
71PositiveBalance Sheet
76PositiveCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.14B | 13.64B | 12.61B | 11.81B | 11.23B | 9.86B |
| Gross Profit | 1.64B | 1.56B | 1.44B | 1.31B | 1.24B | 1.02B |
| EBITDA | 433.22M | 360.38M | 417.85M | 401.82M | 353.41M | 294.45M |
| Net Income | 196.51M | 155.58M | 154.24M | 146.27M | 137.24M | 150.66M |
Balance Sheet | ||||||
| Total Assets | 6.23B | 6.33B | 5.51B | 5.18B | 4.84B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 137.31M | 168.62M | 143.94M | 119.55M | 225.87M | 89.18M |
| Total Debt | 797.46M | 853.32M | 448.57M | 663.43M | 378.08M | 176.59M |
| Total Liabilities | 4.90B | 5.06B | 4.10B | 4.12B | 3.91B | 3.23B |
| Stockholders Equity | 1.12B | 1.06B | 1.14B | 990.36M | 880.24M | 847.29M |
Cash Flow | ||||||
| Free Cash Flow | 231.35M | 371.66M | -29.68M | 194.09M | 254.49M | 247.45M |
| Operating Cash Flow | 360.91M | 496.54M | 63.23M | 288.27M | 335.94M | 300.20M |
| Investing Cash Flow | -281.59M | -323.45M | -198.10M | -257.03M | -180.22M | -145.49M |
| Financing Cash Flow | -119.54M | -144.95M | 139.62M | -139.09M | -6.64M | -112.76M |
NEUCA S.A. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:NEU, the sentiment is Neutral. The current price of 708.00 is above the 20-day moving average (MA) of 698.95, below the 50-day MA of 714.84, and below the 200-day MA of 720.97, indicating a neutral trend. The MACD of -5.48 indicates Negative momentum. The RSI at 50.46 is Neutral, neither overbought nor oversold. The STOCH value of 59.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PL:NEU.
NEUCA S.A. Peers Comparison
Overall Rating
PL:NEU61Neutral
PL:BIO45Neutral
PL:CLN42Neutral
PL:MAB41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | PLN 3.24B | 16.32 | 18.10% | 2.53% | 8.42% | 43.47% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | PLN 293.66M | -24.89 | -1.97% | ― | -15.67% | -307.60% | |
| 42Neutral | PLN 861.51M | 7.61 | 24.89% | ― | ― | ― | |
| 41Neutral | PLN 163.56M | -2.89 | -124.37% | ― | 56.67% | 12.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PL:NEU | NEUCA S.A. | 708.00 | -50.71 | -6.68% | |
| PL:SVE | Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. | 2.84 | -1.17 | -29.09% | |
| PL:CLN | Celon Pharma SA | 15.80 | -5.65 | -26.34% | |
| PL:BIO | BIOTON S.A. | 3.44 | -0.57 | -14.34% | |
| PL:MRC | Mercator Medical SA | 57.50 | 19.10 | 49.74% | |
| PL:MAB | Mabion SA | 10.32 | 2.74 | 36.15% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 16, 2025
